<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002194</url>
  </required_header>
  <id_info>
    <org_study_id>200G</org_study_id>
    <nct_id>NCT00002194</nct_id>
  </id_info>
  <brief_title>An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.</brief_title>
  <official_title>An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the potential pharmacokinetic interaction between nevirapine and clarithromycin,&#xD;
      and to determine the effects of nevirapine on cytochrome P450 3A4 (CYP3A4) activity in vivo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is conducted in two separate groups. Patients in Group I receive clarithromycin&#xD;
      orally for 32 days and nevirapine orally for 28 days.&#xD;
&#xD;
      Patients in Group II receive erythromycin intravenously on days 0, 14, 28, and 43 and&#xD;
      nevirapine orally for 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>36</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        Antiretroviral drugs (i.e., zidovudine, zalcitabine, stavudine, lamivudine, didanosine,&#xD;
        indinavir, saquinavir) provided that there has been no change in dosing of the medication &gt;&#xD;
        25% within 4 weeks of study entry.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV positive status.&#xD;
&#xD;
          -  CD4 count &gt;= 100 cells/mm3.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        Patients may be on clarithromycin at study entry.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions are excluded:&#xD;
&#xD;
        Malabsorption, severe chronic diarrhea, or inability to maintain adequate oral intake.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Macrolide antibiotics (erythromycin, azithromycin, dirithromycin), azole fungals&#xD;
        (ketoconazole, fluconazole, itraconazole), rifampin, rifabutin, phenytoin, terfenadine,&#xD;
        astemizole, cisapride, triazolam, midazolam, other non-nucleoside reverse transcriptase&#xD;
        inhibitors, antibiotics containing clavulanic acid, and Augmentin.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of drug allergy or known drug hypersensitivity.&#xD;
&#xD;
          -  History of clinically important disease including hepatic, renal, cardiovascular, or&#xD;
             gastrointestinal disease.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Investigational drugs or antineoplastic agents within 12 weeks of study entry.&#xD;
&#xD;
          -  Participation in a clinical trial that used ERMBY within one year of study entry.&#xD;
&#xD;
          -  Systemic treatment with drugs known to be potent hepatic enzyme inducers or inhibitors&#xD;
             (e.g., oral macrolide antibiotics, azole antifungals, cimetidine, rifampin, rifabutin,&#xD;
             and carbamazepine) within 28 days of study entry.&#xD;
&#xD;
          -  Use of protease inhibitors; ritonavir, nelfinavir, indinavir, or non-nucleoside&#xD;
             reverse transcriptase inhibitor compounds e.g., delavirdine) within 4 weeks of study&#xD;
             entry.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Radiotherapy within 12 weeks of study entry.&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Current history (within the last year) of IVDA, ETOH, or substance abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>South Florida Bioavailability Clinic</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>331813405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2002</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Antibiotics, Macrolide</keyword>
  <keyword>Clarithromycin</keyword>
  <keyword>Nevirapine</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Cytochrome P-450</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

